AstraZeneca's Lynparza cancer drug approved by Japan
29th Dec 2020 07:02
(Sharecast News) - AstraZeneca and Merck's Lynparza has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers, the UK-based pharmaceutical company said on Tuesday.
Read moreSunday newspaper round-up: AstraZeneca, Boxing Day, Britain's economy
27th Dec 2020 12:39
(Sharecast News) - The chief executive of AstraZeneca has raised hopes its vaccine with Oxford is more effective than first thought amid the rapid spread of the new UK virus strain across the globe. Pascal Soriot said he believed researchers had found the "winning formula" using two doses and promised to publish the results as reports suggested the UK regulator could approve the jab within days. - Sunday Telegraph
Read moreAstraZeneca issues updates on roxadustat and Tagrisso
21st Dec 2020 08:03
(Sharecast News) - Pharmaceutical giant AstraZeneca issued updates on both roxadustat and Tagrisso on Monday, with one drug facing a delay to its application and the other being granted approval in the US.
Read moreThursday broker round-up
17th Dec 2020 13:13
(Sharecast News) - Yellow Cake: Berenberg reiterates buy with a target price of 300p.
Read moreS&P places AstraZeneca's debt on Credit Watch Positive on proposed purchase of Alexion
16th Dec 2020 14:34
(Sharecast News) - Standard&Poor's placed its rating on AstraZeneca's long-term corporate debt on so-called Credit Watch Positive following news of its intended purchase of US rare disease specialist Alexion.
Read moreAstraZeneca gets recommendation for new Imfinzi dosing option
15th Dec 2020 07:17
(Sharecast News) - AstraZeneca announced on Tuesday that 'Imfinzi', or durvalumab, had been recommended for marketing authorisation in the European Union for an additional dosing option.
Read moreSector movers: AstraZeneca leads Big Pharma lower
14th Dec 2020 19:09
(Sharecast News) - Pharmaceuticals paced decliners on Monday as markets reacted poorly to the news of a $39bn cash and shares takeover offer for rare diseases specialist Alexion from the UK's AstraZeneca.
Read moreMonday broker round-up
14th Dec 2020 13:32
(Sharecast News) - Midwich Group: Berenberg reiterates buy with a target price of 550p.
Read moreAstraZeneca gets two more EU drug approvals
14th Dec 2020 07:38
(Sharecast News) - AstraZeneca announced on Monday that 'Trixeo Aerosphere', or formoterol fumarate, glycopyrronium bromide and budesonide, has received approval in the European Union (EU).
Read moreAstraZeneca to buy US drug maker Alexion in $39bn deal
14th Dec 2020 07:01
(Sharecast News) - Pharmaceutical company AstraZeneca said it was buying US drug developer Alexion in a cash and shares deal worth $39bn.
Read moreSunday newspaper round-up: Brexit, Coronavirus, AstraZeneca
13th Dec 2020 18:57
(Sharecast News) - Britain and the EU have taken a step forward towards striking a post-Brexit trade and security deal after Boris Johnson and Ursula von der Leyen agreed to "go the extra mile" and ordered the resumption of talks in Brussels. The prime minister played down expectations following the telephone conversation with the European commission president, telling the cabinet to prepare for a no-deal exit when the transition period ends in three weeks' time. But in Brussels, EU embassies were briefed by the commission that "progress has been made" and that "the next days will be important". - Guardian
Read moreAstraZeneca to explore combination of Covid vaccine with Russian jab
11th Dec 2020 11:43
(Sharecast News) - AstraZeneca was set to start testing a combination of its prospective Covid-19 vaccine and Russia's 'Sputnik V' shot, it was reported on Friday, in a bid to strengthen the efficacy of its vaccine developed in conjunction with Oxford University.
Read moreAstraZeneca sells cholesterol drug rights for up to $350m
1st Dec 2020 07:41
(Sharecast News) - AstraZeneca said it had agreed to sell the rights to its cholesterol treatment Crestor to Germany's Grunenthal for up to $350m (£261m).
Read moreAstraZeneca's 'Forxiga' gets approval in Japan for heart failure
30th Nov 2020 07:43
(Sharecast News) - AstraZeneca announced on Monday that 'Forxiga', or dapagliflozin, has been approved in Japan for the treatment of patients with chronic heart failure, who are receiving standard-of-care.
Read moreFriday broker round-up
27th Nov 2020 13:18
(Sharecast News) - GoCo: Deutsche Bank downgrades to hold with a target price of 1,974p.
Read more